GH Research (GHRS) Shares Outstanding (Weighted Average) (2020 - 2025)
GH Research (GHRS) recorded quarterly Shares Outstanding (Weighted Average) of $454.2 million in Q4 2025, up 81102757.14% quarter-over-quarter from $560.0 in Q3 2025, and up 49.19% on a YoY basis from $304.4 million in Q4 2024.
GH Research (GHRS) Shares Outstanding (Weighted Average) (2020 - 2025) Analysis & Trends
GH Research's Shares Outstanding (Weighted Average) history runs 6 years deep, the most recent figure standing at $454.2 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Weighted Average) rose 49.19% year-over-year to $454.2 million; the TTM figure through Dec 2025 stood at $454.2 million (up 49.19% YoY), while the FY2025 annual figure was $454.2 million, up 772.94% from the prior year.
- Shares Outstanding (Weighted Average) was $454.2 million for Q4 2025 at GH Research, up from $560.0 in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.3 billion in Q1 2022 to a low of $100.0 in Q2 2022.
- Historically, Shares Outstanding (Weighted Average) has averaged $516.2 million across 5 years, with a median of $304.4 million in 2021.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) soared 361388788.89% in 2024, then slumped 100.0% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $304.4 million in 2021, then changed by 0.0% to $304.4 million in 2022, then sank by 82.91% to $52.0 million in 2023, then surged by 485.18% to $304.4 million in 2024, then surged by 49.19% to $454.2 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $454.2 million (Q4 2025), $560.0 (Q3 2025), and $330.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 417.01 Bn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 928.40 Mn |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | 454.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 454.18 Mn |
| Sep 30, 2025 | 560.00 |
| Jun 30, 2025 | 330.00 |
| Mar 31, 2025 | 190.00 |
| Dec 31, 2024 | 304.43 Mn |
| Sep 30, 2024 | 1.30 Bn |
| Jun 30, 2024 | 1.30 Bn |
| Mar 31, 2024 | 1.30 Bn |
| Dec 31, 2023 | 52.02 Mn |
| Sep 30, 2023 | 470.00 |
| Jun 30, 2023 | 360.00 |
| Mar 31, 2023 | 1.30 Bn |
| Dec 31, 2022 | 304.41 Mn |
| Sep 30, 2022 | 1.30 Bn |
| Jun 30, 2022 | 100.00 |
| Mar 31, 2022 | 1.30 Bn |
| Dec 31, 2021 | 304.41 Mn |
| Sep 30, 2021 | 291.45 Mn |
| Jun 30, 2021 | 291.51 Mn |
| Dec 31, 2020 | 5.43 Mn |